Michael Fuchs starts by discussing the value of having a multi-disciplinary mission and vision for patient treatment. From there, the group points to several different approaches — communication, metrics, education — that will be pivotal to driving that kind of vision and making it effective. In the end, the panelists discuss actions they each can take over the next six months to move us closer to realizing the Action Plan vision.
This conversation is sponsored with a grant from Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is leading the field of NASH therapeutic development with resmetirom, a thyroid receptor beta agonist with potential to address both the liver pathophysiology and fibrosis caused by NASH.
TOPICS: AASLD, cirrhosis, Diabetes, Diagnostic Tests, DrugTrial, education, Fatty Liver, FDA, Global Liver Institute, Madrigal, NAFLD, NASH, non-invasive liver testing, Obesity, Patient Advocacy, PNAFLD, social policy,
Surfing The NASH Tsunami is brought to you by HEP Dynamics
#HEPdynamics #SurfingNASH #podcast
